Flamel Technologies SA (NASDAQ:FLML) traded up 3.3% during trading on Thursday . The stock traded as high as $12.66 and last traded at $12.36, with a volume of 137,118 shares trading hands. The stock had previously closed at $11.96.

Several equities research analysts recently commented on the company. Leerink Swann restated an “outperform” rating and set a $16.00 target price on shares of Flamel Technologies SA in a research report on Wednesday, March 23rd. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $18.63.

The stock has a 50-day moving average of $10.53 and a 200 day moving average of $10.49. The stock has a market cap of $512.21 million and a price-to-earnings ratio of 23.52.

Flamel Technologies SA (NASDAQ:FLML) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.10. The business earned $36.20 million during the quarter, compared to analysts’ expectations of $34 million. Flamel Technologies SA’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities research analysts expect that Flamel Technologies SA will post ($0.03) EPS for the current year.

In other news, Director Craig R. Stapleton purchased 27,228 shares of the company’s stock in a transaction on Monday, May 16th. The stock was purchased at an average price of $9.21 per share, with a total value of $250,769.88. Following the completion of the purchase, the director now directly owns 507,263 shares in the company, valued at approximately $4,671,892.23. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction on Thursday, May 12th. The shares were purchased at an average cost of $8.84 per share, with a total value of $44,200.00. Following the purchase, the chief executive officer now owns 134,250 shares of the company’s stock, valued at $1,186,770. The disclosure for this purchase can be found here.

Other large investors have recently modified their holdings of the company. Tekla Capital Management LLC purchased a new stake in shares of Flamel Technologies SA during the fourth quarter valued at about $5,791,000. Morgan Stanley increased its position in Flamel Technologies SA by 131.4% in the fourth quarter. Morgan Stanley now owns 719,463 shares of the company’s stock valued at $8,785,000 after buying an additional 408,531 shares in the last quarter. Heartland Advisors Inc. bought a new position in Flamel Technologies SA during the fourth quarter valued at approximately $3,053,000. Sei Investments Co. bought a new position in Flamel Technologies SA during the fourth quarter valued at approximately $2,129,000. Finally, Turner Investments L.P. increased its position in Flamel Technologies SA by 77.3% in the fourth quarter. Turner Investments L.P. now owns 239,308 shares of the company’s stock valued at $2,922,000 after buying an additional 104,340 shares in the last quarter.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.